Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults >= 65 Years of Age
NCT00966238
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
120
Enrollment
INDUSTRY
Sponsor class
Conditions
Influenza
Interventions
BIOLOGICAL:
VAX125
Sponsor
VaxInnate Corporation